Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.

C. Garufi, F. Lévi, S. Giunta, A. Aschelter, R. Pace, C. Nisticò, E. Terzoli

Research output: Contribution to journalArticle

Abstract

The best schedule for administering floxuridine (FUDR) has not yet been established. Duration of infusion, need (and dosage) of leucovorin (folinic acid, FA), and circadian timing need to be further specified. Nevertheless, FUDR delivery according to circadian rhythms has allowed increase of dose intensity without enhancing the side effects. A 5-day infusional schedule combining FUDR and L-FA was devised as an attempt to increase dose intensity and to provide therapy every 3 weeks to patients with advanced cancer. An ambulatory programmable-in-time pump was used for this purpose. Fourteen patients entered this trial. Two dose levels (mg/kg x 5 days) were evaluated: 0.5 mg/kg/day in six patients and 0.525 mg/kg/day in eight patients. Both patient groups received a concurrent infusion of L-FA 10 mg/m2/day i.v. The delivery patterns of both FUDR and L-FA varied sinusoidally during the 24 hours with a maximum at 18.00 hours. Courses were repeated every 3 weeks. Of 35 courses, treatment produced mucosites greater than grade 2 in only two of them. No severe diarrhea, the dose-limiting toxicity of FUDR when infused over 14 days, was encountered at the dose levels tested. This 5-day chronotherapy schedule allowed delivery of a larger amount of FUDR than the flat delivery described in a previous report. A daily dose of 0.525 mg/kg FUDR, combined with 10 mg/mg2 L-FA, with intraindividual dose escalation according to tolerance, is recommended for future investigations of the activity of this chronotherapy schedule.

Original languageEnglish
Pages (from-to)134-137
Number of pages4
JournalThe Journal of infusional chemotherapy
Volume5
Issue number3 Suppl 1
Publication statusPublished - 1995

Fingerprint

Floxuridine
Leucovorin
Feasibility Studies
Appointments and Schedules
Chronotherapy
Neoplasms
Circadian Rhythm
Diarrhea
Therapeutics

ASJC Scopus subject areas

  • Microbiology

Cite this

Garufi, C., Lévi, F., Giunta, S., Aschelter, A., Pace, R., Nisticò, C., & Terzoli, E. (1995). Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study. The Journal of infusional chemotherapy, 5(3 Suppl 1), 134-137.

Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies : a feasibility and tolerability study. / Garufi, C.; Lévi, F.; Giunta, S.; Aschelter, A.; Pace, R.; Nisticò, C.; Terzoli, E.

In: The Journal of infusional chemotherapy, Vol. 5, No. 3 Suppl 1, 1995, p. 134-137.

Research output: Contribution to journalArticle

Garufi, C, Lévi, F, Giunta, S, Aschelter, A, Pace, R, Nisticò, C & Terzoli, E 1995, 'Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.', The Journal of infusional chemotherapy, vol. 5, no. 3 Suppl 1, pp. 134-137.
Garufi, C. ; Lévi, F. ; Giunta, S. ; Aschelter, A. ; Pace, R. ; Nisticò, C. ; Terzoli, E. / Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies : a feasibility and tolerability study. In: The Journal of infusional chemotherapy. 1995 ; Vol. 5, No. 3 Suppl 1. pp. 134-137.
@article{0b6554a3665a4ae7a216106f4c575f5c,
title = "Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.",
abstract = "The best schedule for administering floxuridine (FUDR) has not yet been established. Duration of infusion, need (and dosage) of leucovorin (folinic acid, FA), and circadian timing need to be further specified. Nevertheless, FUDR delivery according to circadian rhythms has allowed increase of dose intensity without enhancing the side effects. A 5-day infusional schedule combining FUDR and L-FA was devised as an attempt to increase dose intensity and to provide therapy every 3 weeks to patients with advanced cancer. An ambulatory programmable-in-time pump was used for this purpose. Fourteen patients entered this trial. Two dose levels (mg/kg x 5 days) were evaluated: 0.5 mg/kg/day in six patients and 0.525 mg/kg/day in eight patients. Both patient groups received a concurrent infusion of L-FA 10 mg/m2/day i.v. The delivery patterns of both FUDR and L-FA varied sinusoidally during the 24 hours with a maximum at 18.00 hours. Courses were repeated every 3 weeks. Of 35 courses, treatment produced mucosites greater than grade 2 in only two of them. No severe diarrhea, the dose-limiting toxicity of FUDR when infused over 14 days, was encountered at the dose levels tested. This 5-day chronotherapy schedule allowed delivery of a larger amount of FUDR than the flat delivery described in a previous report. A daily dose of 0.525 mg/kg FUDR, combined with 10 mg/mg2 L-FA, with intraindividual dose escalation according to tolerance, is recommended for future investigations of the activity of this chronotherapy schedule.",
author = "C. Garufi and F. L{\'e}vi and S. Giunta and A. Aschelter and R. Pace and C. Nistic{\`o} and E. Terzoli",
year = "1995",
language = "English",
volume = "5",
pages = "134--137",
journal = "Journal of Spirochetal and Tick-borne Diseases",
issn = "1060-0051",
publisher = "Slack Incorporated",
number = "3 Suppl 1",

}

TY - JOUR

T1 - Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies

T2 - a feasibility and tolerability study.

AU - Garufi, C.

AU - Lévi, F.

AU - Giunta, S.

AU - Aschelter, A.

AU - Pace, R.

AU - Nisticò, C.

AU - Terzoli, E.

PY - 1995

Y1 - 1995

N2 - The best schedule for administering floxuridine (FUDR) has not yet been established. Duration of infusion, need (and dosage) of leucovorin (folinic acid, FA), and circadian timing need to be further specified. Nevertheless, FUDR delivery according to circadian rhythms has allowed increase of dose intensity without enhancing the side effects. A 5-day infusional schedule combining FUDR and L-FA was devised as an attempt to increase dose intensity and to provide therapy every 3 weeks to patients with advanced cancer. An ambulatory programmable-in-time pump was used for this purpose. Fourteen patients entered this trial. Two dose levels (mg/kg x 5 days) were evaluated: 0.5 mg/kg/day in six patients and 0.525 mg/kg/day in eight patients. Both patient groups received a concurrent infusion of L-FA 10 mg/m2/day i.v. The delivery patterns of both FUDR and L-FA varied sinusoidally during the 24 hours with a maximum at 18.00 hours. Courses were repeated every 3 weeks. Of 35 courses, treatment produced mucosites greater than grade 2 in only two of them. No severe diarrhea, the dose-limiting toxicity of FUDR when infused over 14 days, was encountered at the dose levels tested. This 5-day chronotherapy schedule allowed delivery of a larger amount of FUDR than the flat delivery described in a previous report. A daily dose of 0.525 mg/kg FUDR, combined with 10 mg/mg2 L-FA, with intraindividual dose escalation according to tolerance, is recommended for future investigations of the activity of this chronotherapy schedule.

AB - The best schedule for administering floxuridine (FUDR) has not yet been established. Duration of infusion, need (and dosage) of leucovorin (folinic acid, FA), and circadian timing need to be further specified. Nevertheless, FUDR delivery according to circadian rhythms has allowed increase of dose intensity without enhancing the side effects. A 5-day infusional schedule combining FUDR and L-FA was devised as an attempt to increase dose intensity and to provide therapy every 3 weeks to patients with advanced cancer. An ambulatory programmable-in-time pump was used for this purpose. Fourteen patients entered this trial. Two dose levels (mg/kg x 5 days) were evaluated: 0.5 mg/kg/day in six patients and 0.525 mg/kg/day in eight patients. Both patient groups received a concurrent infusion of L-FA 10 mg/m2/day i.v. The delivery patterns of both FUDR and L-FA varied sinusoidally during the 24 hours with a maximum at 18.00 hours. Courses were repeated every 3 weeks. Of 35 courses, treatment produced mucosites greater than grade 2 in only two of them. No severe diarrhea, the dose-limiting toxicity of FUDR when infused over 14 days, was encountered at the dose levels tested. This 5-day chronotherapy schedule allowed delivery of a larger amount of FUDR than the flat delivery described in a previous report. A daily dose of 0.525 mg/kg FUDR, combined with 10 mg/mg2 L-FA, with intraindividual dose escalation according to tolerance, is recommended for future investigations of the activity of this chronotherapy schedule.

UR - http://www.scopus.com/inward/record.url?scp=0029435934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029435934&partnerID=8YFLogxK

M3 - Article

C2 - 8528973

AN - SCOPUS:0029435934

VL - 5

SP - 134

EP - 137

JO - Journal of Spirochetal and Tick-borne Diseases

JF - Journal of Spirochetal and Tick-borne Diseases

SN - 1060-0051

IS - 3 Suppl 1

ER -